Results 111 to 120 of about 5,685 (219)

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function

, 2001
OBJECTIVESThe goal of this study was to evaluate platelet function and to preliminarily assess the clinical safety of sequential treatment with tirofiban or eptifibatide followed by abciximab in patients undergoing percutaneous coronary intervention (PCI)
Osende, Julio I, Jayasundera, Tim, Sharma, Samin K, Richard, Merwin F, Badimon, Juan J, Robbins, Jonathan A, Rodriguez, Oswaldo, Marmur, Jonathan D, Lev, Eli I, Delfin, Jenny A   +9 more
core   +1 more source

Endovascular treatment combined with eptifibatide in patients with acute ischemic stroke: a prospective, multicenter study

Chinese Journal of Contemporary Neurology and Neurosurgery
Objective To explore the efficacy and safety of endovascular treatment (EVT) combined with eptifibatide in the treatment of acute ischemic stroke. Methods This study enrolled the 102 acute ischemic stroke patients at 15 centers in China received EVT ...
HU Xiao⁃yan, LUO Yu⁃qi, MIAO Yan, GAO Feng, MA Ning, SUN Xuan   +5 more
doaj   +1 more source

Combined Effects of Eptifibatide and Anticoagulants: Differences between LMWH and UH or rH in Thrombin Generation Inhibition but not in Platelet Aggregation Inhibition

, 2002
SummaryAim of our study was to investigate effects of eptifibatide and anticoagulants on platelet aggregation and thrombin generation under low and high coagulant challenge in tissue factor-activated platelet rich plasma using a model allowing ...
Gerhard Cvirn, Martin Koestenberger, Bettina Leschnik, Martina Petritsch, Wolfgang Muntean, Birgit Roschitz, Siegfried Gallistl   +6 more
core   +1 more source

Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction Results of the CLEAR PLATELETS-2 (Clopidogrel With Eptifibatide to Arrest the Reactivity of Platelets) Study

, 2009
ObjectivesThe primary objective of this study was to compare the effect of therapy with bivalirudin alone versus bivalirudin plus eptifibatide on platelet reactivity measured by turbidometric aggregometry and thrombin-induced platelet-fibrin clot ...
Bassi, Ashwani K., Bliden, Kevin P., Hennebry, Thomas A., Suarez, Thomas A., Herzog, William R., Gurbel, Paul A., DiChiara, Joseph, Antonino, Mark J., Tantry, Udaya S., Saucedo, Jorge F., Mahla, Elisabeth, Gesheff, Tania B., Singla, Anand   +12 more
core   +1 more source

Safety and efficacy of adjunctive tirofiban and eptifibatide in acute ischemic stroke: A systematic review and meta-analysis

Journal of Stroke and Cerebrovascular Diseases
Introduction and Objective: Acute ischemic stroke (AIS) is one of the most common cerebrovascular diseases, posing a substantial burden on public health systems and individuals. Tirofiban and eptifibatide are used alongside intravenous thrombolysis (IVT)
Hameer Ali, Rida Shehzad, Usama Ahmed, Yahya Abualown, Wajida Perveen, Junaid Gulzar, Saad Azam, Zain ul Abideen, Shah e Zaman, Umair Hayat, Uzair Jafar, Muhammad Ehsan, Bilawal Nadeem, Ankit Agrawal, Raheel Ahmed   +14 more
doaj   +1 more source

Eptifibatide Bolus Dose During Elective Percutaneous Coronary Intervention

Background: Eptifibatide is a platelet glycoprotein IIb/IIIa receptor antagonist used for the prevention of cardiac ischemic complications of percutaneous coronary intervention (PCI). Eptifibatide has been used with bolus dose only or bolus plus infusion
دوستکامی, حسین, صادقیه اهری, سعید, ایرانی جم, عفت, حبیب زاده, افشین   +3 more
core  

Eptifibatide-Induced Thrombocytopenia: With Thrombosis and Disseminated Intravascular Coagulation Immediately After Left Main Coronary Artery Percutaneous Coronary Angioplasty

, 2012
Early clinical trials of eptifibatide did not show a significant association between eptifibatide and the development of thrombocytopenia, thrombosis, or disseminated intravascular coagulation.
Tempelhof, Michael W, Fintel, Dan, Benzuly, Keith H, Krichavsky, Marc Z   +3 more
core  

Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators

, 2000
BACKGROUND: Platelet glycoprotein (GP) IIb/IIIa antagonists prevent the composite end point of death or myocardial infarction (MI) in patients with acute coronary syndromes.
Berdan, L.G. (Lisa), Topol, E.J. (Eric), Lorenz, T.J., Wilcox, R.G. (Robert), Simoons, M.L. (Maarten), Kleiman, N.S. (Neal), Boersma, H. (Eric), Flaker, G.C., Cokkinos, D.V. (Dennis), Pieper, K.S. (Karen), Harrington, R.A. (Robert Alex), Califf, R.M. (Robert), Lincoff, A.M. (Michael)   +12 more
core  

Commentary: Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data. [PDF]

Front Med (Lausanne)
Feng Y, Li LC, Niu XF, Lin HH.
europepmc   +1 more source

Eptifibatide: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Intervention and Acute Coronary Syndromes

Eptifibatide (Integrilin(R)) is a selective inhibitor of platelet glycoprotein (GP) IIb/IIIa receptors used as adjunctive therapy for patients undergoing percutaneous coronary intervention (PCI) and for patients with acute coronary syndromes (ACS ...
Greg L. Plosker, Tim Ibbotson
core